Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.

Bruce talks about how his time working in a lab at the Children’s Hospital of Philadelphia inspired him to work on translational therapies. Together, they also discuss barriers to access for cancer therapeutics and how the fight against cancer is progressing.

Additional disclosures for Bruce include:

Scientific Advisory Boards: Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, UTC Therapeutics. Scientific Advisor: Kite. Past: Akron, Vycellix

Co-Founder and equity holder: Tmunity Therapeutics (acquired by Kite), Capstan Therapeutics

Board of Directors: Alliance for Cancer Gene Therapy

Conflict of interest is managed in accordance with University of Pennsylvania policy and oversight.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.